Summary
William Snider, a director at Harvard Bioscience Inc (NASDAQ: HBIO), made two insider purchases on March 16 and March 17, 2026, that together total $103,603. Following these acquisitions, Snider directly owns 32,000 shares of the company. The stock is trading below analyst targets and the company recently published fourth-quarter 2025 results and 2026 guidance.
Details of the insider transactions
Snider executed purchases across two days:
- On March 16, 2026, he acquired 12,525 shares at a weighted average price of $4.99 per share, in multiple transactions with execution prices ranging from $4.85 to $5.00. The aggregate value of this tranche was $62,500.
- On March 17, 2026, he bought an additional 8,475 shares at a weighted average price of $4.85 per share, with trade prices between $4.80 and $4.95. The total reported cost for that day was $41,103.
Combined, the two transactions are recorded as "P" transactions totaling $103,603. After these purchases, Snider holds 32,000 shares directly.
Market context and analyst perspective
The insider buying occurred while HBIO shares were trading at $4.87, representing a 28% decline year-to-date. According to InvestingPro data cited by the company reporting, analysts maintain a price target of $6.00 for HBIO, implying upside from the then-current share price. The InvestingPro platform also notes that Harvard Bioscience's liquid assets exceed short-term obligations, an observation highlighted among other metrics in its Pro Research Report covering HBIO and more than 1,400 US equities.
Financial results and 2026 outlook
Harvard Bioscience reported fourth-quarter 2025 revenue of $23.7 million, which exceeded the midpoint of management's guidance range but still represented a 3.2% decline compared with the prior year. The company posted a gross margin of 59.77% for the quarter, the highest level recorded in seven quarters.
For 2026, Harvard Bioscience provided guidance that calls for revenue growth of 2% to 4%, which translates to a target range of $88 million to $90 million. Management expects gross margins to fall between 58% and 60% and projects adjusted EBITDA growth of 6% to 10%, corresponding to $8.6 million to $8.9 million.
Analyst actions and strategic priorities
Benchmark adjusted its price target for Harvard Bioscience to $6.00 following a 1-for-10 reverse stock split, while maintaining a Speculative Buy rating. Previously, Benchmark had reduced its target to $0.60 citing concerns linked to NIH budget issues and a conservative outlook for 2026.
Harvard Bioscience has outlined strategic priorities for 2026 that emphasize revenue expansion and margin improvement through manufacturing consolidation and new product introductions. Those initiatives are cited as part of the company s plan to improve operating results.
What this means in plain terms
The transactions increase a director's direct exposure to the equity while the company reports a mixed set of results - revenue slightly down year-over-year but with improving gross margins and a modest growth outlook for the coming year. Analysts' maintained price targets and Benchmark's ratings change are part of the context in which the insider purchases were made. Investors and market observers will likely weigh these factors alongside the stock's year-to-date decline and the company's execution on its 2026 plans.